{"id":"amikacin-inhalation","safety":{"commonSideEffects":[{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Bronchospasm"},{"rate":null,"effect":"Wheezing"},{"rate":null,"effect":"Dyspnea"},{"rate":null,"effect":"Ototoxicity (with systemic absorption)"},{"rate":null,"effect":"Nephrotoxicity (with systemic absorption)"}]},"_chembl":{"chemblId":"CHEMBL4208954","moleculeType":"Small molecule","molecularWeight":"781.77"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amikacin irreversibly binds to the 30S ribosomal subunit of susceptible bacteria, disrupting protein synthesis and causing bactericidal activity. The inhalation formulation delivers the drug directly to the lungs, achieving high local concentrations to treat respiratory tract infections, particularly in cystic fibrosis and chronic Pseudomonas aeruginosa infections.","oneSentence":"Amikacin is an aminoglycoside antibiotic that binds to bacterial ribosomes and inhibits protein synthesis, leading to bacterial cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:00.489Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cystic fibrosis with chronic Pseudomonas aeruginosa lung infection"},{"name":"Chronic respiratory tract infections caused by susceptible gram-negative bacteria"}]},"trialDetails":[{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT04677569","phase":"PHASE3","title":"Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2021-04-01","conditions":"Mycobacterium Infections, Nontuberculous","enrollment":425},{"nctId":"NCT07369336","phase":"PHASE4","title":"Clinical Outcomes of Inhaled Amikacin in Ventilator Associated Pneumonia","status":"COMPLETED","sponsor":"Postgraduate Medical Institute, Lahore","startDate":"2024-01-05","conditions":"Ventilator Associated Pneumonia ( VAP)","enrollment":90},{"nctId":"NCT03149640","phase":"PHASE3","title":"Study Comparing Inhaled Amikacin Versus Placebo to Prevent Ventilator Associated Pneumonia","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2017-07-19","conditions":"Pneumonia, Ventilator-Associated","enrollment":850},{"nctId":"NCT06585020","phase":"PHASE2","title":"Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2024-10-20","conditions":"Mycobacterium; Xenopi, Lung Diseases","enrollment":190},{"nctId":"NCT06418711","phase":"PHASE3","title":"ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension","status":"TERMINATED","sponsor":"Mannkind Corporation","startDate":"2024-09-11","conditions":"MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous","enrollment":132},{"nctId":"NCT04310930","phase":"PHASE2, PHASE3","title":"Finding the Optimal Regimen for Mycobacterium Abscessus Treatment","status":"RECRUITING","sponsor":"The University of Queensland","startDate":"2020-03-02","conditions":"Pulmonary Disease Due to Mycobacteria (Diagnosis)","enrollment":300},{"nctId":"NCT06808074","phase":"PHASE4","title":"A Study to Evaluate Role of Inhaled Amikacin to Prevent Ventilator Associated Pneumonia in Patients With Cirrhosis","status":"RECRUITING","sponsor":"Asian Institute of Gastroenterology, India","startDate":"2025-02-12","conditions":"Hepatic Encephalopathy, Cirrhosis, Ventilator Associated Pneumonia (VAP)","enrollment":162},{"nctId":"NCT06106789","phase":"","title":"A Study of the Clinical Benefit of Tobramycin Inhalation Solution","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qianfoshan Hospital","startDate":"2023-04-01","conditions":"Bronchiectasis, Cystic Fibrosis, Lung Infection","enrollment":1600},{"nctId":"NCT06602557","phase":"PHASE2","title":"\" a Randomized Pilot Study of the Benefit of Nebulized Amikacin in the Treatment of Gram-negative Bacillus Pneumonia Acquired During Mechanical Ventilation in Patients Receiving Extracorporeal Membrane Veno-arterial Oxygenation (ECMO-VA).\"","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-11-15","conditions":"Pneumonia, Bacterial, Extracorporeal Membrane Oxygenation","enrollment":26},{"nctId":"NCT04677543","phase":"PHASE3","title":"Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2020-12-22","conditions":"Mycobacterium Infections, Nontuberculous","enrollment":99},{"nctId":"NCT06238856","phase":"PHASE1","title":"Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas Aeruginosa","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2004-05-12","conditions":"Cystic Fibrosis","enrollment":18},{"nctId":"NCT05999942","phase":"PHASE1","title":"A Study to Investigate Lung Deposition of Inhaled Amikacin-loaded Liposomes in Healthy Male Participants","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2004-06-02","conditions":"Healthy Volunteers","enrollment":6},{"nctId":"NCT03449459","phase":"EARLY_PHASE1","title":"Prevention of Acute Exacerbation in Subjects With COPD by Bacterial Decolonization in Lower Respiratory Tract","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2018-12-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":144},{"nctId":"NCT05213507","phase":"PHASE3","title":"Inhaled Amikacin in Preventing AECOPD","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-03","conditions":"COPD, COPD Exacerbation","enrollment":136},{"nctId":"NCT04249531","phase":"PHASE1","title":"Pharmacokinetic Evaluation and Local Tolerability of Dry Powder Amikacin Via the Cyclops™","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2020-06-01","conditions":"Tuberculosis","enrollment":8},{"nctId":"NCT00777296","phase":"PHASE1, PHASE2","title":"Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2007-02-22","conditions":"Cystic Fibrosis","enrollment":66},{"nctId":"NCT03905642","phase":"PHASE2","title":"Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension Phase","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2009-01-08","conditions":"Cystic Fibrosis","enrollment":49},{"nctId":"NCT01316276","phase":"PHASE3","title":"Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2012-10-05","conditions":"Cystic Fibrosis","enrollment":206},{"nctId":"NCT01315678","phase":"PHASE3","title":"Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2012-02-29","conditions":"Pseudomonas Aeruginosa Infection","enrollment":302},{"nctId":"NCT02344004","phase":"PHASE3","title":"Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2015-05-27","conditions":"Mycobacterium Infections, Nontuberculous","enrollment":336},{"nctId":"NCT03038178","phase":"PHASE2","title":"Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease","status":"COMPLETED","sponsor":"Kevin Winthrop","startDate":"2016-10","conditions":"Mycobacterium Infections, Nontuberculous, Mycobacteria, Atypical","enrollment":30},{"nctId":"NCT04163601","phase":"","title":"Liposomal Amikacin Inhalation in M.Abscessus Patients","status":"UNKNOWN","sponsor":"University Hospital, Montpellier","startDate":"2019-11-30","conditions":"M.Abscessus Pulmonary Disease","enrollment":400},{"nctId":"NCT02628600","phase":"PHASE3","title":"Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2016-02-05","conditions":"NTM Lung Infection Due to MAC","enrollment":163},{"nctId":"NCT01315236","phase":"PHASE2","title":"Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2012-04-19","conditions":"Mycobacterium Infections, Nontuberculous","enrollment":90},{"nctId":"NCT00775138","phase":"PHASE2","title":"Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2008-06-24","conditions":"Bronchiectasis","enrollment":64},{"nctId":"NCT00558844","phase":"PHASE1, PHASE2","title":"Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2008-01","conditions":"Cystic Fibrosis","enrollment":41},{"nctId":"NCT03921645","phase":"NA","title":"Use of Aaerosol Combined With Intravenous Antibiotics for the Treatment of Multidrug Resistant GNB Pneumonia","status":"UNKNOWN","sponsor":"Shanghai 10th People's Hospital","startDate":"2018-01-01","conditions":"Ventilator Associated Pneumonia, Multi-antibiotic Resistance","enrollment":60},{"nctId":"NCT03622450","phase":"PHASE2, PHASE3","title":"The Effect of Colistin Inhalation on Ventilator Associated Pneumonia","status":"COMPLETED","sponsor":"Nourhan Hassan Osama Thuraya Mohamed","startDate":"2016-01-02","conditions":"Ventilator Associated Pneumonia","enrollment":40},{"nctId":"NCT01315691","phase":"PHASE3","title":"Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa","status":"WITHDRAWN","sponsor":"Insmed Incorporated","startDate":"","conditions":"Cystic Fibrosis","enrollment":""},{"nctId":"NCT01799993","phase":"PHASE3","title":"Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-04-13","conditions":"Pneumonia, Bacterial","enrollment":725},{"nctId":"NCT01969799","phase":"PHASE2","title":"Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia","status":"COMPLETED","sponsor":"Cardeas Pharma","startDate":"2013-12","conditions":"Pneumonia, Bacterial","enrollment":143},{"nctId":"NCT01021436","phase":"PHASE2","title":"Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-ventilated Patients With Nosocomial Pneumonia","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-03","conditions":"Pneumonia","enrollment":30},{"nctId":"NCT02218359","phase":"PHASE2","title":"Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative and / or Gram-positive Bacterial Colonization","status":"WITHDRAWN","sponsor":"Cardeas Pharma","startDate":"2014-10","conditions":"Pneumonia, Bacterial","enrollment":""},{"nctId":"NCT02084043","phase":"NA","title":"In Vitro Assessment of a Breath-synchronized Vibrating Mesh Nebulizer During Non Invasive Ventilation","status":"COMPLETED","sponsor":"University Hospital St Luc, Brussels","startDate":"2014-03","conditions":"Respiratory Diseases, Lung Diseases, Cystic Fibrosis","enrollment":3},{"nctId":"NCT02277808","phase":"EARLY_PHASE1","title":"Which Apparatus for Inhaled Pentamidine?","status":"UNKNOWN","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2013-12","conditions":"Healthy","enrollment":10},{"nctId":"NCT01528930","phase":"PHASE2","title":"Inhaled Amikacin Treatment for Nontuberculous Mycobacterial Lung Disease","status":"WITHDRAWN","sponsor":"Samsung Medical Center","startDate":"2012-02","conditions":"Pulmonary Non-tuberculous Mycobacterial Lung Disease","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ACUTE KIDNEY INJURY"},{"count":1,"reaction":"CONDITION AGGRAVATED"},{"count":1,"reaction":"DRUG INEFFECTIVE"},{"count":1,"reaction":"HYPERCAPNIA"},{"count":1,"reaction":"LUNG INFECTION"},{"count":1,"reaction":"RESPIRATORY GAS EXCHANGE DISORDER"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Amikacin (Inhalation)","genericName":"Amikacin (Inhalation)","companyName":"The University of Queensland","companyId":"the-university-of-queensland","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amikacin is an aminoglycoside antibiotic that binds to bacterial ribosomes and inhibits protein synthesis, leading to bacterial cell death. Used for Cystic fibrosis with chronic Pseudomonas aeruginosa lung infection, Chronic respiratory tract infections caused by susceptible gram-negative bacteria.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}